Systematic analysis of expression profiles of HMGB family members for prognostic application in non-small cell lung cancer

por Zheng, Xuefeng, Wang, Xu, He, Yunduan, Ge, Hong
Publicado 2022

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

por Lv, Huifang, He, Yunduan, Nie, Caiyun, Du, Feng, Chen, Xiaobing
Publicado 2023

Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma

por Xu, Weifeng, Nie, Caiyun, Lv, Huifang, Chen, BeiBei, Wang, Jianzheng, Wang, Saiqi, Zhao, Jing, He, Yunduan, Chen, Xiaobing
Publicado 2022

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above thera...

por Nie, Caiyun, Lv, Huifang, Chen, Beibei, Xu, Weifeng, Wang, Jianzheng, Liu, Yingjun, Wang, Saiqi, Zhao, Jing, He, Yunduan, Chen, Xiaobing
Publicado 2022

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study

por Nie, Caiyun, Lv, Huifang, Chen, Beibei, Xu, Weifeng, Wang, Jianzheng, Wang, Saiqi, Liu, Yingjun, He, Yunduan, Zhao, Jing, Chen, Xiaobing
Publicado 2023

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study

por Nie, Caiyun, He, Yunduan, Lv, Huifang, Gao, Ming, Gao, Xiaohui, Chen, Beibei, Xu, Weifeng, Wang, Jianzheng, Liu, Yingjun, Zhao, Jing, Chen, Xiaobing
Publicado 2022

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer

por Chen, Beibei, Zhao, Huichen, Huang, Jinxi, Lv, Huifang, Xu, Weifeng, Nie, Caiyun, Wang, Jianzheng, Zhao, Jing, He, Yunduan, Wang, Saiqi, Chen, Xiaobing
Publicado 2022

Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors

por Wang, Jianzheng, Zhang, Baiwen, Cheng, Xiaojiao, Li, Qingli, Lv, Huifang, Nie, Caiyun, Chen, Beibei, Xu, Weifeng, Zhao, Jing, He, Yunduan, Tu, Shuiping, Chen, Xiaobing
Publicado 2022

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

por Wang, Jianzheng, He, Yunduan, Zhang, Baiwen, Lv, Huifang, Nie, Caiyun, Chen, Beibei, Xu, Weifeng, Zhao, Jing, Cheng, Xiaojiao, Li, Qingli, Tu, Shuiping, Chen, Xiaobing
Publicado 2022

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study

por Nie, Caiyun, Xu, Weifeng, Lv, Huifang, Gao, Xiaohui, Li, Guofeng, Chen, Beibei, Wang, Jianzheng, Liu, Yingjun, Zhao, Jing, He, Yunduan, Wang, Saiqi, Chen, Xiaobing
Publicado 2022

Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications

por Zhao, Huichen, Hu, Huihui, Chen, Beibei, Xu, Weifeng, Zhao, Jing, Huang, Chen, Xing, Yishu, Lv, Huifang, Nie, Caiyun, Wang, Jianzheng, He, Yunduan, Wang, Sai-Qi, Chen, Xiao-Bing
Publicado 2021